




# NCCN Clinical Practice Guidelines: Unresectable and Metastatic Cholangiocarcinoma<sup>1</sup>

Full abbreviations, accreditation, and disclosure information available at [PeerView.com/GUS40](https://www.peerview.com/GUS40)

PeerView  
Oncology





PRACTICE AID

# Selected Targeted Therapies in Biliary Cancers<sup>1-12</sup>

Full abbreviations, accreditation, and disclosure information available at [PeerView.com/GUS40](https://www.peerview.com/GUS40)

PeerView  
Oncology



| <br><b>Target</b> | <br><b>Agent</b> | <br><b>Efficacy</b> | <br><b>Safety</b><br><i>(Common Adverse Events)</i> |
|----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| <b>FGFR</b>                                                                                        | Pemigatinib<br><b>FDA approved</b>                                                                | <b>FIGHT-202</b><br>ORR: 37.0%                                                                         | Hyperphosphatemia, alopecia, diarrhea, nail toxicity, fatigue, dysgeusia, nausea                                                       |
|                                                                                                    | Infigratinib<br><b>FDA approved</b>                                                               | <b>PROOF</b><br>ORR: 23.1%                                                                             | Hyperphosphatemia, nail toxicity, stomatitis, dry eye, eye toxicity, fatigue                                                           |
|                                                                                                    | Futibatinib<br><b>FDA approved</b>                                                                | <b>FOENIX-CCA2</b><br>ORR: 41.7%                                                                       | Hyperphosphatemia, diarrhea, dry mouth                                                                                                 |
|                                                                                                    | Derazantinib                                                                                      | <b>FIDES-01</b><br>ORR: 21.4%; mPFS: 8.3 mo                                                            | Asthenia/fatigue, eye toxicity, hyperphosphatemia                                                                                      |
|                                                                                                    | Erdafitinib                                                                                       | <b>RAGNAR</b><br>ORR: 60%                                                                              | Stomatitis, PPE, hyperphosphatemia, diarrhea                                                                                           |
| <b>IDH</b>                                                                                         | Ivosidenib<br><b>FDA approved</b>                                                                 | <b>ClarIDHy</b><br>mPFS: 2.7 mo; mOS: 10.3 mo                                                          | Nausea, diarrhea, fatigue, abdominal pain, ascites                                                                                     |
| <b>BRAF V600E</b>                                                                                  | Dabrafenib + trametinib<br><b>FDA approved</b>                                                    | <b>ROAR</b><br>ORR: 53.0%                                                                              | Pyrexia, fatigue, chills, nausea, rash                                                                                                 |
| <b>KRAS G12C</b>                                                                                   | Adagrasib                                                                                         | <b>KRYSTAL-1</b><br>ORR: 41.7                                                                          | Nausea, diarrhea, fatigue, vomiting                                                                                                    |



PRACTICE AID

# Selected Targeted Therapies in Biliary Cancers<sup>1-12</sup>

Full abbreviations, accreditation, and disclosure information available at [PeerView.com/GUS40](https://www.peerview.com/GUS40)

PeerView  
Oncology



| <br><b>Target</b> | <br><b>Agent</b> | <br><b>Efficacy</b> | <br><b>Safety</b><br><i>(Common Adverse Events)</i> |
|----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| <b>HER2</b>                                                                                        | Pertuzumab + trastuzumab                                                                          | <b>MyPathway</b><br>ORR: 23%                                                                           | Elevated liver enzymes,<br>increased bilirubin                                                                                         |
|                                                                                                    | Trastuzumab deruxtecan<br><i>Breakthrough therapy<br/>designation</i>                             | <b>HERB</b><br>ORR: 36.4%                                                                              | Elevated liver enzymes,<br>nausea, fatigue, vomiting, ILD                                                                              |
|                                                                                                    | Zanidatamab<br><i>Breakthrough therapy<br/>designation</i>                                        | <b>DESTINY-PanTumor02</b><br>ORR (IHC3+): 56.3%;<br>ORR (all): 22.0%                                   |                                                                                                                                        |
|                                                                                                    |                                                                                                   | <b>HERIZON-BTC-01</b><br>ORR (IHC 2+ or 3+): 41.3%                                                     | Diarrhea, IRR,<br>decreased ejection fraction                                                                                          |

1. Vogel et al. *Ann Oncol.* 2022;33(suppl 4):S379. 2. Javle M et al. *Lancet.* 2021;6:803-815. 3. Goyal L et al. *N Engl J Med.* 2023;388:228-239. 4. Borad M et al. *Ann Oncol.* 2022;33(suppl 7):S567-S568. 5. Pant S et al. *J Clin Oncol.* 2023;41(suppl 4):610. 6. Abou-Alfa G et al. *J Clin Oncol.* 2021;39(suppl 15):4069. 7. Subbiah V et al. *Nature.* 2023;29:1103-1112. 8. Bekaii-Saab T et al. *J Clin Oncol.* 2023;41:4097-4106. 9. Javle M et al. *Lancet.* 2021;22:1290-1300. 10. Ohba A et al. *J Clin Oncol.* 2022;40(suppl 16):4006. 11. Meric-Bernstam F et al. *J Clin Oncol.* 2024;42:47-58. 12. Harding J et al. *Lancet.* 2023;24:772-782.

## **Patient-centered education is vital to optimizing outcomes in patients with biliary tract cancers (BTCs).**

The printable resource on the following page is for you to share with patients and caregivers. It outlines helpful support options provided by the Cholangiocarcinoma Foundation.



**Printable Resource on Next Page**

1. <https://cholangiocarcinoma.org/mutationsmatter/patients-portal>.

# Have you or your loved one been diagnosed with a bile duct cancer?

Patient Education

The below resources from the Cholangiocarcinoma Foundation (CCF) may help support you on the treatment journey.

**The Cholangiocarcinoma Foundation's mission is to find a cure and improve the quality of life for those affected by cholangiocarcinoma (bile duct cancer).**



Visit <https://cholangiocarcinoma.org> for multiple resources that patients can use to:

- Get the latest information about their disease
- Connect with other patients
- Participate in clinical trials

And much more



## Selected resources include




### International Cholangiocarcinoma Patient Registry (ICPR)

<https://cholangiocarcinoma.org/international-cholangiocarcinoma-patient-registry-icpr>

#### Specialist Map

Select a state below to view NCI designated healthcare organizations and healthcare providers that specialize in cholangiocarcinoma.



### Find a Specialist

<https://cholangiocarcinoma.org/specialist-map>



#### First Line Therapy

The first treatment given for disease.



#### Beyond First Line Therapy

These trials available after discontinuation of first line therapy.



#### Chemotherapy

Trials with treatment of disease by the use of chemical substances, or cytotoxic and other drugs.



#### Targeted Therapy

Trials that target specific genes or proteins.

### Find and Learn About Clinical Trials

<https://cholangiocarcinoma.org/professionals/research/clinical-trials>

**Always contact your healthcare provider or care team with specific questions or concerns.**